Cancer combo trial halted early: what went wrong?

NCT ID NCT03446040

Terminated Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the trial was terminated early, meaning it stopped before completion, so we don't have full results on how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986258 (an experimental biologic) and nivolumab (Opdivo, an immunotherapy)
What this could lead to: If it had succeeded, this could have pointed toward a new combination treatment for certain advanced cancers.
What could go wrong: The trial was terminated early, so results are limited. It was a small, early-phase study focused on safety, not effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer head and neck squamous cell carcinoma non-small cell lung carcinoma renal cell carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

Local Institution - 0002

Germantown, Tennessee, 38138, United States
Local Institution - 0004

Los Angeles, California, 90033, United States
Local Institution - 0005

Pittsburgh, Pennsylvania, 15232, United States
Local Institution - 0006

Los Angeles, California, 90033, United States
Local Institution - 0007

Aurora, Colorado, 80045, United States
Local Institution - 0008

Chuo-ku, Tokyo, 1040045, Japan
Local Institution - 0009

Kobe, Hyōgo, 6500017, Japan
Local Institution - 0010

Grand Rapids, Michigan, 49546, United States
Local Institution - 0012

Lebanon, New Hampshire, 03756, United States
Local Institution - 0013

Westmead, New South Wales, 2145, Australia
Local Institution - 0014

Edmonton, Alberta, T6X 1E8, Canada
Local Institution - 0015

Melbourne, Victoria, 3084, Australia
Local Institution - 0016

Cincinnati, Ohio, 45267, United States
Local Institution - 0018

Ann Arbor, Michigan, 48109-5912, United States
Local Institution - 0019

Vancouver, British Columbia, V5Z 4E6, Canada
University Of Iowa Hospitals And Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.